Lotrel G0.5%+0.3%

Lotrel G ophthalmic suspension is a corticosteroid-antibiotic combination indicated for:

• Established/approved use: Treatment of steroid-responsive inflammatory ocular conditions (such as post-operative inflammation following ocular surgery, e.g., cataract surgery) for which a corticosteroid is indicated and where superficial bacterial ocular infection exists or there is a significant risk of bacterial ocular infection.
• Guideline/clinically-supported use: Blepharoconjunctivitis and blepharokeratoconjunctivitis with a demonstrated or presumed bacterial component accompanied by significant inflammation.
• Adjunct use: As an adjunct to reduce inflammation and prevent secondary bacterial infection during the post-operative recovery period after ophthalmic surgical procedures.

Lotrel G is not indicated for the initial treatment of bacterial conjunctivitis alone (without a clear steroid-responsive inflammatory component), nor as an antibiotic used without concurrent need for the corticosteroid effect. It must not be used to treat infections without adequate concurrent antimicrobial therapy where the infecting organism is not susceptible.

Each mL of sterile ophthalmic suspension of Loteprednol Etabonate + Gatifloxacin typically contains:

• Loteprednol Etabonate 5 mg (0.5% w/v)
• Gatifloxacin 3 mg (0.3% w/v, as gatifloxacin sesquihydrate)

along with pharmaceutically approved preservatives, viscosity-imparting agents, tonicity agents, and buffering excipients suitable for ophthalmic use.

Lotrel G is a fixed-dose, sterile topical ophthalmic suspension combining two active components with complementary actions:

• Loteprednol etabonate is a site-specific ("soft") corticosteroid designed to undergo rapid metabolic deactivation after exerting its anti-inflammatory effect, which is associated with a comparatively lower risk of raising intraocular pressure than some older ophthalmic corticosteroids, although this risk is not eliminated.
• Gatifloxacin is a fourth-generation fluoroquinolone antibiotic with broad-spectrum bactericidal activity against many Gram-positive and Gram-negative ocular pathogens.

The combination is formulated to control ocular inflammation while covering or preventing bacterial infection in appropriate clinical settings, primarily peri-operative and blepharoconjunctivitis care.

Lotrel G belongs to the therapeutic class of ophthalmic corticosteroid–antibiotic combinations, combining a topical corticosteroid (loteprednol etabonate) with a fluoroquinolone antibacterial (gatifloxacin) for combined anti-inflammatory and antimicrobial ocular therapy.

Loteprednol Etabonate + Gatifloxacin combines two agents with distinct mechanisms of action:

Loteprednol Etabonate

Loteprednol etabonate suppresses the inflammatory response to mechanical, chemical, or immunological insults by inhibiting phospholipase A2, thereby reducing the release of arachidonic acid and downstream inflammatory mediators (prostaglandins and leukotrienes). It also reduces capillary dilation, leukocyte migration, fibrin deposition, capillary proliferation, and scar formation associated with inflammation. Its ester structure allows rapid hydrolysis to inactive metabolites, limiting systemic and prolonged ocular exposure.

Gatifloxacin

Gatifloxacin is a fluoroquinolone that exerts bactericidal activity by inhibiting bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes required for bacterial DNA replication, transcription, repair, and recombination. It has activity against many aerobic Gram-positive organisms (e.g., Staphylococcus aureus, Streptococcus pneumoniae) and Gram-negative organisms (e.g., Haemophilus influenzae) commonly implicated in ocular surface infections.

Following topical ocular administration of Loteprednol Etabonate + Gatifloxacin, systemic absorption of both components is generally low, though measurable plasma levels of gatifloxacin can occur; loteprednol etabonate has minimal systemic absorption due to rapid ocular and systemic metabolism.

Lotrel G is for topical ophthalmic (eye) use only — it must not be injected, ingested, or applied to any other body site. Shake the bottle well before each use, avoid touching the dropper tip to any surface (including the eye), and apply gentle punctal occlusion after instillation. Do not wear contact lenses during active infection/inflammation being treated; consult the physician about when lens wear may resume.

Formal drug-drug interaction studies with Lotrel G are limited, but the following are clinically relevant considerations:

• Other topical ophthalmic products: Concurrent use of other topical ophthalmic corticosteroids or NSAIDs may increase the risk of elevated intraocular pressure and delayed corneal/wound healing; space administration of multiple ophthalmic products by at least 5–10 minutes.
• Systemic fluoroquinolones or QT-prolonging drugs: Although systemic absorption from ophthalmic gatifloxacin is low, caution is advised with concurrent use of systemic drugs known to prolong the QT interval, as a theoretical additive risk exists.
• Live or attenuated ocular vaccines/immunosuppressive therapy: Concomitant use with other immunosuppressive or antiviral ocular therapies should be supervised by an ophthalmologist due to the corticosteroid's effect on local immune response.

Inform the physician of all ophthalmic and systemic medications in use before starting Lotrel G.

Reported adverse effects with Lotrel G include:

Common

• Ocular discomfort, stinging, or burning on instillation
• Eye pain or irritation
• Blurred vision (transient)
• Foreign body sensation
• Ocular itching, redness, or dryness

Less common/serious

• Elevated intraocular pressure (see Precautions and Warnings)
• Posterior subcapsular cataract formation with prolonged use
• Delayed wound healing
• Secondary ocular infection (fungal or viral) following suppression of the host response
• Hypersensitivity reactions (eyelid swelling, itching, rash)

Patients should report any worsening eye pain, vision changes, persistent redness, or signs of new infection promptly.

Pregnancy: There are no adequate and well-controlled studies of Lotrel G in pregnant women. Systemic absorption from topical ophthalmic use is expected to be low; nonetheless, this product should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus, and only under a physician's advice.

Lactation: It is not known whether topically applied loteprednol etabonate or gatifloxacin is excreted in human milk in clinically significant amounts. Caution should be exercised, and Lotrel G should be used during breastfeeding only after consulting a physician, weighing the benefit against any potential risk to the nursing infant.

The following precautions apply to the use of Lotrel G:

• Intraocular pressure (IOP): Prolonged use of any topical corticosteroid, including the loteprednol component, may result in elevated IOP and/or glaucoma with optic nerve damage, and can cause posterior subcapsular cataract formation. Intraocular pressure should be monitored periodically, especially with courses beyond 10–14 days.
• Delayed wound healing: Corticosteroids may slow corneal and scleral wound healing; use with caution following ocular surgery, and monitor healing progress.
• Masking or exacerbation of infection: Use of corticosteroid-containing products may suppress the clinical signs of infection or exacerbate an existing untreated ocular infection (bacterial, viral, or fungal), particularly with prolonged use. Secondary ocular infections may develop, including fungal keratitis, which should be suspected in any persistent corneal ulceration despite therapy.
• Not for injection or oral use: For topical ophthalmic use only.
• Antibiotic stewardship: Take Lotrel G exactly as prescribed by your physician; do not stop, extend, skip doses, or share this medicine with others without medical advice, to reduce the risk of antibiotic resistance and treatment failure.
• Contact lenses: Avoid wearing contact lenses during treatment of active ocular inflammation/infection unless the physician advises otherwise.
• Hypersensitivity: Discontinue immediately and seek medical advice if signs of hypersensitivity occur (see Contraindications).

Topical ocular overdose of Lotrel G is unlikely to cause acute systemic toxicity, but excessive or prolonged use may increase the risk of intraocular pressure elevation, cataract formation, and other corticosteroid-related ocular effects. If accidental oral ingestion occurs, or if excessive instillation causes marked ocular irritation, pain, or vision changes, seek immediate medical attention or contact a poison control center/emergency services. The affected eye(s) may be flushed with clean water or normal saline as a general first-aid measure while awaiting medical advice; do not attempt specific home treatment beyond this.

Store at room temperature (below 30°C), away from light and moisture. Do not freeze. Keep the bottle tightly closed when not in use, and keep out of reach of children. Discard any remaining suspension after the physician-directed treatment course or per the expiry/discard date on the label, whichever is sooner.

Pediatric use

Safety and efficacy of Lotrel G in pediatric patients below 1 year of age have not been established. In older children in whom a steroid-responsive inflammatory ocular condition with bacterial infection risk exists, use should be under close ophthalmologic supervision, at the physician's discretion, with the same dosing principles as adults adjusted to clinical need.

Elderly (geriatric) use

No overall differences in safety or effectiveness have been reported between elderly and younger adult patients; standard adult dosing is generally applicable.

Renal/hepatic impairment

Given the low systemic absorption of both components after topical ophthalmic administration, no specific dosage adjustment is generally required in renal or hepatic impairment; however, caution and physician judgment are advised.

Contact lens wearers

Contact lens use should generally be avoided during active treatment with Lotrel G unless otherwise directed by the physician.

Treatment duration with Lotrel G is individualized by the prescribing ophthalmologist based on the severity of inflammation and infection risk, typically ranging from several days up to about 1–2 weeks, with tapering of dose as inflammation resolves. Treatment should not be continued beyond the prescribed duration without re-evaluation, given the risk of corticosteroid-related ocular complications with prolonged use.

Ophthalmic corticosteroid (loteprednol etabonate) combined with a fourth-generation fluoroquinolone antibiotic (gatifloxacin); classified as an ophthalmic anti-inflammatory/anti-infective combination.

Loteprednol Etabonate + Gatifloxacin acts through two complementary mechanisms: loteprednol etabonate inhibits phospholipase A2 to suppress the arachidonic acid inflammatory cascade (reducing prostaglandin and leukotriene production, capillary permeability, and leukocyte infiltration), while gatifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, blocking bacterial DNA replication and leading to bactericidal activity against susceptible ocular pathogens.

Safety and efficacy of Lotrel G have not been established in children below 1 year of age. Use in older pediatric patients should be guided and supervised by an ophthalmologist, following the same clinical principles as adult use, adjusted for the child's condition and monitored closely for intraocular pressure changes and local tolerance.